[
  {
    "ts": null,
    "headline": "ZBH Stock Might Rise Following FDA Nod for OsseoFit",
    "summary": "Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=09aef9a0fa4dcb519cc4eddfb58d3446e49955666752f321586e757f4bdd7138",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734352500,
      "headline": "ZBH Stock Might Rise Following FDA Nod for OsseoFit",
      "id": 132011490,
      "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=09aef9a0fa4dcb519cc4eddfb58d3446e49955666752f321586e757f4bdd7138"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Select Mid Cap Growth Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Select Mid Cap Growth Fundâs Class Y shares returned 5.38% for the third quarter, while the Fundâs benchmark, the Russell Index, returned 6.54%.",
    "url": "https://finnhub.io/api/news?id=38eb011b723ab43c3bc40c30ba8208da56d6ed5f227f9e2957aa6bd605a9e8b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734340260,
      "headline": "Pioneer Select Mid Cap Growth Fund Q3 2024 Performance And Market Commentary",
      "id": 132011140,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2169953259/image_2169953259.jpg?io=getty-c-w1536",
      "related": "RMD",
      "source": "SeekingAlpha",
      "summary": "Pioneer Select Mid Cap Growth Fundâs Class Y shares returned 5.38% for the third quarter, while the Fundâs benchmark, the Russell Index, returned 6.54%.",
      "url": "https://finnhub.io/api/news?id=38eb011b723ab43c3bc40c30ba8208da56d6ed5f227f9e2957aa6bd605a9e8b9"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss drugs draw Americans back to the doctor",
    "summary": "Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other...",
    "url": "https://finnhub.io/api/news?id=ac2059f7af1009c2673ec205bce2da4759c28773a22e1177e93421999db788a7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734329138,
      "headline": "Weight-loss drugs draw Americans back to the doctor",
      "id": 132009542,
      "image": "",
      "related": "RMD",
      "source": "Finnhub",
      "summary": "Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other...",
      "url": "https://finnhub.io/api/news?id=ac2059f7af1009c2673ec205bce2da4759c28773a22e1177e93421999db788a7"
    }
  }
]